🇺🇸 FDA
Patent

US 6207690

Troglitazone compounds for treating climacteric and cancer

expired A61KA61K31/426A61K31/427

Quick answer

US patent 6207690 (Troglitazone compounds for treating climacteric and cancer) held by The Board of Regents of the University of Texas System expires Mon Mar 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Mar 27 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/426, A61K31/427, A61K31/4439, A61P